First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry
Background: The biolimus-eluting stent (BES) was the first to elute anti-proliferative drug from a biodegradable polymer. In the randomized LEADERS trial, a stainless steel BES showed non-inferior efficacy compared to a sirolimus-eluting stent and a long-term safety advantage. We report the first cl...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-02-01
|
Series: | International Journal of Cardiology: Heart & Vasculature |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235290672030004X |
id |
doaj-0b54c11e43934e80814b6554ea0f35ab |
---|---|
record_format |
Article |
spelling |
doaj-0b54c11e43934e80814b6554ea0f35ab2020-11-25T00:35:11ZengElsevierInternational Journal of Cardiology: Heart & Vasculature2352-90672020-02-0126First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registryIan B.A. Menown0Mamas A. Mamas1James M. Cotton2David Hildick-Smith3Franz R. Eberli4Gregor Leibundgut5Damras Tresukosol6Carlos Macaya7Samuel Copt8Sara Sadozai Slama9Hans-Peter Stoll10Craigavon Cardiac Centre & Queens University Belfast, UK; Corresponding author at: Craigavon Cardiac Centre, Craigavon, N. Ireland BT63 5QQ, UK.University Hospital of North Midlands NHS Trust, Keele Cardiovascular Research Group, Keele University, UKRoyal Wolverhampton NHS Trust, UKBrighton and Sussex University Hospitals, UKTriemli Hospital, SwitzerlandKantonsspital Baselland, SwitzerlandHer Majesty Cardiac Center, ThailandHospital Clinico San Carlos, SpainBiosensors Clinical Research, Morges, SwitzerlandBiosensors Clinical Research, Morges, SwitzerlandBiosensors Clinical Research, Morges, SwitzerlandBackground: The biolimus-eluting stent (BES) was the first to elute anti-proliferative drug from a biodegradable polymer. In the randomized LEADERS trial, a stainless steel BES showed non-inferior efficacy compared to a sirolimus-eluting stent and a long-term safety advantage. We report the first clinical efficacy and safety outcomes of a new thin-strut cobalt chromium biolimus-eluting stent (CoCr-BES) from an international multi-centre registry. Methods: We studied 400 all-comer patients with coronary disease receiving CoCr-BES at 12 centres, with follow-up at 9 months and 2 years. The primary endpoint was incidence of major adverse cardiac events (MACE) at 9 months comprising cardiac death, myocardial infarction (MI), and clinically indicated target vessel revascularization (ci-TVR). Key protocol elements were the same as the randomized LEADERS trial to enable a historical control for propensity-matched comparison. Results: Mean patient age was 65 ± 11 years, 19% had diabetes, and 55% presented with unstable angina or MI. On discharge, 96% of patients were on dual antiplatelet therapy (DAPT) and 69% were on DAPT at 9 months. MACE at 9 months occurred in 3.9% of patients, cardiac death in 0.8%, MI in 1.1% and ci-TVR in 2.7%. One patient (0.25%) experienced definite or probable stent thrombosis (ST). A propensity-adjusted comparison showed similar clinical outcomes to the BES arm in the LEADERS trial for the primary endpoint MACE. Conclusions: The new CoCr-BES showed low rates of MACE, MI, ci-TVR and ST at 9 months, similar to the BES arm in LEADERS. Keywords: Drug eluting stent, Biodegradable polymer, Cobalt-chromium, Strut thickness, Myocardial infarction, Stent thrombosishttp://www.sciencedirect.com/science/article/pii/S235290672030004X |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ian B.A. Menown Mamas A. Mamas James M. Cotton David Hildick-Smith Franz R. Eberli Gregor Leibundgut Damras Tresukosol Carlos Macaya Samuel Copt Sara Sadozai Slama Hans-Peter Stoll |
spellingShingle |
Ian B.A. Menown Mamas A. Mamas James M. Cotton David Hildick-Smith Franz R. Eberli Gregor Leibundgut Damras Tresukosol Carlos Macaya Samuel Copt Sara Sadozai Slama Hans-Peter Stoll First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry International Journal of Cardiology: Heart & Vasculature |
author_facet |
Ian B.A. Menown Mamas A. Mamas James M. Cotton David Hildick-Smith Franz R. Eberli Gregor Leibundgut Damras Tresukosol Carlos Macaya Samuel Copt Sara Sadozai Slama Hans-Peter Stoll |
author_sort |
Ian B.A. Menown |
title |
First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry |
title_short |
First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry |
title_full |
First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry |
title_fullStr |
First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry |
title_full_unstemmed |
First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry |
title_sort |
first clinical evidence characterizing safety and efficacy of the new cocr biolimus-a9 eluting stent: the biomatrix alpha™ registry |
publisher |
Elsevier |
series |
International Journal of Cardiology: Heart & Vasculature |
issn |
2352-9067 |
publishDate |
2020-02-01 |
description |
Background: The biolimus-eluting stent (BES) was the first to elute anti-proliferative drug from a biodegradable polymer. In the randomized LEADERS trial, a stainless steel BES showed non-inferior efficacy compared to a sirolimus-eluting stent and a long-term safety advantage. We report the first clinical efficacy and safety outcomes of a new thin-strut cobalt chromium biolimus-eluting stent (CoCr-BES) from an international multi-centre registry. Methods: We studied 400 all-comer patients with coronary disease receiving CoCr-BES at 12 centres, with follow-up at 9 months and 2 years. The primary endpoint was incidence of major adverse cardiac events (MACE) at 9 months comprising cardiac death, myocardial infarction (MI), and clinically indicated target vessel revascularization (ci-TVR). Key protocol elements were the same as the randomized LEADERS trial to enable a historical control for propensity-matched comparison. Results: Mean patient age was 65 ± 11 years, 19% had diabetes, and 55% presented with unstable angina or MI. On discharge, 96% of patients were on dual antiplatelet therapy (DAPT) and 69% were on DAPT at 9 months. MACE at 9 months occurred in 3.9% of patients, cardiac death in 0.8%, MI in 1.1% and ci-TVR in 2.7%. One patient (0.25%) experienced definite or probable stent thrombosis (ST). A propensity-adjusted comparison showed similar clinical outcomes to the BES arm in the LEADERS trial for the primary endpoint MACE. Conclusions: The new CoCr-BES showed low rates of MACE, MI, ci-TVR and ST at 9 months, similar to the BES arm in LEADERS. Keywords: Drug eluting stent, Biodegradable polymer, Cobalt-chromium, Strut thickness, Myocardial infarction, Stent thrombosis |
url |
http://www.sciencedirect.com/science/article/pii/S235290672030004X |
work_keys_str_mv |
AT ianbamenown firstclinicalevidencecharacterizingsafetyandefficacyofthenewcocrbiolimusa9elutingstentthebiomatrixalpharegistry AT mamasamamas firstclinicalevidencecharacterizingsafetyandefficacyofthenewcocrbiolimusa9elutingstentthebiomatrixalpharegistry AT jamesmcotton firstclinicalevidencecharacterizingsafetyandefficacyofthenewcocrbiolimusa9elutingstentthebiomatrixalpharegistry AT davidhildicksmith firstclinicalevidencecharacterizingsafetyandefficacyofthenewcocrbiolimusa9elutingstentthebiomatrixalpharegistry AT franzreberli firstclinicalevidencecharacterizingsafetyandefficacyofthenewcocrbiolimusa9elutingstentthebiomatrixalpharegistry AT gregorleibundgut firstclinicalevidencecharacterizingsafetyandefficacyofthenewcocrbiolimusa9elutingstentthebiomatrixalpharegistry AT damrastresukosol firstclinicalevidencecharacterizingsafetyandefficacyofthenewcocrbiolimusa9elutingstentthebiomatrixalpharegistry AT carlosmacaya firstclinicalevidencecharacterizingsafetyandefficacyofthenewcocrbiolimusa9elutingstentthebiomatrixalpharegistry AT samuelcopt firstclinicalevidencecharacterizingsafetyandefficacyofthenewcocrbiolimusa9elutingstentthebiomatrixalpharegistry AT sarasadozaislama firstclinicalevidencecharacterizingsafetyandefficacyofthenewcocrbiolimusa9elutingstentthebiomatrixalpharegistry AT hanspeterstoll firstclinicalevidencecharacterizingsafetyandefficacyofthenewcocrbiolimusa9elutingstentthebiomatrixalpharegistry |
_version_ |
1725309895186579456 |